Novel Drug & Emergent Therapeutics | Pharma | Oncology | Leukaemia
FDA approves revumenib for relapsed or refractory acute leukaemia with a KMT2A translocation
Published on MedED: 18 November 2024
Originally published: 15 November 2024
Source: FDA Press Release
Type of article: Novel Drug & Emergent Therapy News
MedED Catalogue Reference: MNDR001
Category: Oncology
Crossreference: Haematology
Category tags: leukaemia, gene therapy, refractory acute leukaemia
| Product Category | Product Name | Company | Status |
|---|---|---|---|
| FDA Approved |
15 November 2024, FDA Press Release
Among transfusion-dependent patients at baseline, 14% achieved transfusion independence, while 48% of those initially independent maintained this status during follow-up.
Clinical Trials & Supporting Information
| Clinical Study State | ClinicalTrial.gov Registration | Study Name |
|---|---|---|
|
|
Access Original Press Release
15 November 2024 | FDA Press Release | FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation
Access Company Press Release
15 November 2024 | Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
Disclaimer
This article is compiled from a variety of resources. Every effort has been made to correctly attribute quotes and content. Where possible all information has been independently verified. The Medical Education Network bears no responsibility for any inaccuracies which may occur from the use of third-party sources. If you have any queries regarding this article contact us
Fact-checking Policy
The Medical Education Network makes every effort to review and fact-check the articles used as source material in our summaries and original material. We have strict guidelines in relation to the publications we use as our source data, favouring peer-reviewed research wherever possible. Every effort is made to ensure that the information contained here is an accurate reflection of the original material. Should you find inaccuracies, out of date content or have any additional issues with our articles, please make use of the contact us form to notify us.
